Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash
Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash
Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash
Submitted by
admin
on January 27, 2009 - 9:41am
Source:
Yahoo
News Tags:
Astellas
CV Therapeutics
buyouts
Headline:
Astellas Proposes to Acquire CV Therapeutics for $16 Per Share in Cash
Do Not Allow Advertisers to Use My Personal information
